Investment Summary |
|
|---|---|
| Date | 2024-07-16 |
| Target | Asceneuron |
| Sector | Life Science |
| Investor(s) | EQT Life Sciences |
| Deal Type | Growth Capital |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Growth Capital Firm |
|---|---|
| Founded | 1987 |
| PE ASSETS | 2.0B USD |
| Size | Large |
| Type | Sector Focused |
| DEAL STATS | # |
|---|---|
| Overall | 47 of 47 |
| Sector (Life Science) | 30 of 30 |
| Type (Growth Capital) | 5 of 5 |
| Country (Switzerland) | 3 of 3 |
| Year (2024) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-03-25 |
Cardior
Hannover, Germany Cardior is a clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair, and reverse diseases of the heart. The company's therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. Cardior was founded in 2016 and is based in Hannover, Germany. |
Sell | $1.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-08-08 |
Lumeon
Boston, Massachusetts, United States Lumeon enables healthcare organizations to orchestrate and automate systems and processes, bringing situational awareness to care operations to deliver high-performance, team-centered healthcare. Lumeon Care Pathway Management (CPM) platform and suite of solutions empower health organizations to take control of their end-to-end care delivery model and maximize the use of resources. Lumeon was founded in 2005 and is based in Boston, Massachusetts. |
Sell | - |
